Related by context. All words. (Click for frequent words.) 74 Hsp# Inhibitor 74 Panzem R 73 Initiates Phase II 73 HDAC Inhibitor 73 Kinase Inhibitor 73 Successfully Completes Phase 72 tubulin inhibitor 72 Completes Patient Enrollment 72 Presents Preclinical Data 72 Files IND 72 Reports Preclinical Data 72 Phase 2b Clinical Trial 72 pralatrexate injection folate analogue 72 Immunotherapeutic 72 Initiates Clinical Trial 72 Systemic Delivery 72 kidney urologic 72 Anti Tumor 71 TKB# 71 Aurora Kinase 71 IMiDs ® 71 Initiates Clinical 71 Tyrosine Kinase Inhibitor 71 investigational humanized monoclonal antibody 71 candidate deforolimus 71 novel histone deacetylase 71 AAG geldanamycin analog 71 Archexin 71 Initiates Enrollment 71 CCR9 antagonist 70 JAK2 Inhibitor 70 Granted Orphan Drug 70 PI3K/Akt pathway inhibitor 70 highly selective inhibitor 70 Prolongs Survival 70 Phase #b/#a clinical 70 JAK1 70 Personalized Immunotherapy 70 Receives Orphan Drug Designation 70 Small Molecule 70 GVAX ® 70 DNA methyltransferase inhibitors 70 oral prodrug 70 CYT# potent vascular disrupting 70 mitogen activated ERK kinase 70 NPC 1C 70 RNAi Therapeutic 70 Talabostat 70 FOLOTYN ® 70 MEK inhibitor 70 ThermoDox R 70 Meets Primary Endpoint 70 agonistic human 70 Locked Nucleic Acid 70 Initiates Phase III 70 AKT inhibitor 70 selective kinase inhibitor 69 Combination REOLYSIN R 69 drug pipeline TAFA# 69 NS5b 69 Squalamine 69 reversible inhibitor 69 IMC #B 69 Factor Receptor 69 IMiDs R 69 5 HT6 receptor 69 oral picoplatin 69 mTOR mammalian target 69 rxRNA 69 Phase 2b Trial 69 antisense inhibitors 69 Recombinant Human 69 Begins Dosing 69 enhance ApoA 69 accumulate preferentially 69 PF # [002] 69 Phase Ib II 69 orally administered inhibitor 69 MEK inhibitors 69 Antigen Specific 69 Phase 2a Clinical Trial 69 novel antimitotic agent 69 DP VPA 69 Ridaforolimus 69 2 methoxyestradiol 69 Curaxin CBLC# 69 telomerase therapeutic 69 cathepsin K inhibitor 69 Cloretazine ® 69 Submits NDA 69 Histone Deacetylase 69 Panzem ® 69 novel tubulin binding 69 Janus kinase 69 Presents Preclinical 69 Sapacitabine 68 Novel Oral 68 sodium glucose cotransporter 68 ENMD # 68 Antitumor 68 selective immunoproteasome inhibitor 68 isoform selective 68 mertansine 68 lexidronam injection 68 Presents Positive 68 Present Preclinical Data 68 Bazedoxifene 68 Receives Milestone Payment 68 ALN PCS 68 fosbretabulin 68 ThermoDox ® clinical 68 PI3K/mTOR 68 Commences Phase 68 platform HDL Mimetic 68 Cetrorelix 68 Solazed TM 68 Phase III Clinical Trial 68 targeting CD# 68 Epothilones 68 Anti CD# Antibody 68 Exherin TM 68 Anticancer Drug 68 novel emulsion formulation 68 Arno Therapeutics 68 non nucleoside inhibitor 68 R#/MEM # 68 Antibody Drug Conjugate 68 XL# XL# 68 XL# anticancer compounds 68 Crofelemer budesonide foam 68 CD# CEA 68 Initiates Phase 68 Aplidin R 68 Pivotal Phase III 68 Therapeutic Vaccine 68 Selective Electrochemical Tumor Ablation 68 recombinant biopharmaceutical 68 ALN TTR 68 MCSP respectively 68 pan HDAC inhibitor 68 oncolytic virus therapies 68 ZFP Therapeutics 68 Onconase 68 Omacetaxine 68 Aflibercept 68 Factor VIIa 68 receptor tyrosine kinase inhibitor 68 VEGFR2 inhibitor 68 including eniluracil ADH 67 product platforms AZX# 67 KSP inhibitor 67 Aptamer 67 Prodrug 67 Clinical Trial Results 67 humanized monoclonal 67 Initiate Phase 67 Ceflatonin R 67 Tumour Vascular Disrupting Agent 67 sarcoma melanoma 67 trastuzumab DM1 T DM1 67 RNAi Therapeutics 67 Trial Evaluating 67 Trastuzumab DM1 67 peptidic compound 67 PDE4 inhibitor 67 Crit Rev 67 MEK Inhibitor 67 liposomal formulation 67 HDL Selective Delipidation 67 Oral Calcitonin 67 TAFA# 67 rALLy clinical trial 67 HGS# 67 Receives Orphan Drug 67 Protein Kinase C 67 defensin mimetic antibiotic 67 ALTROPANE R 67 Submits Response 67 Cathepsin S 67 OvaRex R 67 Initiates Dosing 67 Ozarelix 67 IgG1 monoclonal antibody 67 Phase IIb Clinical Trial 67 Rigel R# 67 Drug Candidate 67 signal transduction inhibitor 67 HCV RNA polymerase 67 MKC# MT 67 Announces Poster Presentations 67 5 HT2A inverse 67 hypoxia activated prodrug 67 polysaccharide polymer 67 mda 7 67 nasal decolonization 67 AZD# ARRY # 67 Kosan dependence 67 evaluating picoplatin 67 Aganocide 67 Hedgehog Pathway Inhibitor 67 Bayer HealthCare Onyx Pharmaceuticals 67 Elagolix 67 Apaziquone 67 Antiangiogenic 67 TRO# 67 targeted radiotherapeutic 67 apricitabine ATC 67 Vaccine Adjuvant 67 mGluR2 NAM 67 SinuNase ™ 67 Aeolus Pharmaceuticals Announces 67 novel VDA molecule 67 multi kinase inhibitor 67 Achieves Primary Endpoint 67 KL4 Surfactant 67 Phase 2a Trial 67 initiated Phase Ib 67 ATRA IV 67 BXT # 67 Vascugel 67 CCX# 67 Phase III Pivotal 67 novel immunomodulatory 67 antimitotic 67 Demonstrates Significant 67 Alfacell proprietary ribonuclease 67 Panzem R NCD 67 OTCBB PYTO 67 IL# PE#QQR 67 pan histone deacetylase 67 vascular disrupting agents 67 OXi# 67 Monoclonal Antibody 67 PDX pralatrexate 67 aurora kinase 67 Xcytrin R 67 Hepatitis C Virus HCV 67 Myolimus 67 hyaluronidase enzyme 66 Epidermal Growth Factor Receptor 66 protein tyrosine phosphatase 1B 66 specific lectin receptors 66 IAP inhibitor 66 Vascular Disrupting Agent 66 vinca alkaloid 66 Phase 1b Clinical Trial 66 5 HT2A serotonin 66 Files Investigational 66 Intravenous Human 66 targeted antifolate 66 Adnectin 66 apoptosis inducer 66 Preclinical Study 66 Completes Dosing 66 LymphoStat B belimumab 66 potent suppressor 66 Lenocta 66 ADP receptor antagonist 66 anticancer compound 66 sulfonylhydrazine class 66 oral dihydropyrimidine dehydrogenase DPD 66 Preclinical Data 66 oral ghrelin agonist 66 Tesetaxel 66 INSPIRE Trial Phase III 66 Pivotal Phase 66 Advanced Renal Cell 66 YONDELIS R 66 ALN HPN 66 candidates Azedra TM 66 2 inhibitor CYT# 66 essential thrombocythemia ET 66 Adjuvant Treatment 66 Silodosin 66 Myocet 66 HER1 66 Liprotamase 66 ZK EPO 66 Curaxin 66 PHX# 66 Telik logo TELINTRA 66 Preclinical Evaluation 66 MAGE A3 ASCI 66 NEBIDO R 66 Romidepsin 66 selectin antagonist 66 HDL Mimetic Peptide 66 Immunomodulatory 66 vaccine GRNVAC1 66 LymphoStat B TM 66 Demonstrates Potential 66 Tezampanel 66 HDAC enzymes 66 candidate CRLX# 66 PSN# [002] 66 Novel Therapeutic 66 TELINTRA R 66 Develops Novel 66 TRAIL receptor antibodies 66 Shows Promise Against 66 reversible inhibitors 66 Varespladib 66 telomerase inhibitor drug 66 Liposomal 66 XL# XL# XL# XL# 66 Bosutinib 66 IAP inhibitors 66 monoclonal antibody conjugated 66 histone deacetylase 66 Antitumor Activity 66 demonstrated antitumor activity 66 MOVIPREP R 66 BioSante Pharmaceuticals Announces 66 selective orally bioavailable 66 Forodesine 66 Darinaparsin 66 Bezielle 66 non nucleoside HCV 66 Novel Antibody 66 Kinase Inhibitors 66 sodium thiosulfate STS 66 Bafetinib 66 AEG# 66 novel therapeutic antibodies 66 PNP inhibitor 66 triggers apoptosis programmed 66 Ophthotech 66 Tumor Targeting 66 Bioral Amphotericin B 66 Novel Inhibitor 66 Hedgehog pathway inhibitor 66 Patient Enrollment 66 cMET 66 Initiate Clinical Trial 66 Dose Escalation 66 Receptors GPCRs 66 Ceragenin ™ 66 oral proteasome inhibitor 66 Aganocide ® 66 Submits IND 66 immunotherapeutic vaccine 66 Hepatocellular Carcinoma 66 Collaborators Present 66 PROSTASCINT R 66 siRNAs targeting 66 PDE# 66 SuperAntibody 66 alpha folate receptor 66 5 HT2C 66 Pathway Inhibitor 66 Cancer Vaccines 66 Commence Phase 66 Exelixis compounds 66 tiapamil 66 ONCONASE R 66 RAS MAPK pathway 66 small molecule agonists 66 MKC# MKC# PP 66 First Patient Dosed 66 humanized anti 66 IMC A# 66 Bruton tyrosine kinase 66 acetonide FA 66 3 registrational trial 66 Ostabolin C TM 66 novel peptides 66 class anticancer quinolone 66 small molecule thrombopoietin 66 HDACi 66 anti CD3 66 Akt inhibitor 66 dasatinib Sprycel 66 lymphoid malignancies 65 histone deacetylase inhibitor 65 5 lipoxygenase activating 65 Ultrafast Insulin 65 huC# DM4 65 Licenses Novel 65 LibiGel ® 65 Evoltra ® 65 Perifosine 65 CORT # 65 small molecule defensin 65 Valortim TM 65 Submits Biologics License Application 65 BZL# 65 Lenocta TM 65 human IgG1 monoclonal 65 therapeutic monoclonal antibody 65 Prodarsan R 65 Initiates Clinical Trials 65 Completes Enrollment 65 Patients Treated With 65 YONDELIS 65 Antisense 65 PROGENSA R 65 Initiates Phase 2b 65 progressive metastatic prostate 65 Initiated Phase 65 topoisomerase II inhibitor 65 compound INCB# 65 mGluR5 negative 65 Alvine Pharmaceuticals 65 Fleximer 65 Proc Am Soc 65 Vidofludimus 65 Therapeutic Competitors Companies 65 Exherin 65 HGS ETR2 65 P#X# antagonist 65 Hematological Malignancies 65 Preclinical Models 65 IMPDH inhibitor 65 Oral Formulation 65 acadesine 65 PKC# 65 Deforolimus 65 Ep CAM 65 INS# [001] 65 AQ4N 65 Therapeutic Protein 65 huN# DM1 65 Protease Inhibitor 65 GW# [003] 65 MT#/MEDI-# 65 Novolimus 65 Glufosfamide 65 brivanib 65 EVIZON TM 65 targets Galectin receptors 65 Randomized Double blind 65 Xanafide 65 Miraxion Amarin lead 65 anionic backbone 65 metastatic colorectal 65 antibody MT# 65 activin receptor type 65 RAF kinase 65 dasatinib Sprycel ® 65 RELOVAIR ™ 65 Marqibo TM 65 Fibroblast 65 Potelligent Technology 65 Phase Ib Clinical Trial 65 Abstract Accepted 65 antibody MAb 65 immunosuppressive compound 65 proprietary polysaccharide 65 Genasense ® oblimersen 65 JAK2 inhibitor 65 selective modulator 65 Metastatic Melanoma 65 HGS ETR1 mapatumumab 65 PEG SN# 65 THR beta agonist 65 NDA Submission 65 Phase 1b clinical trials 65 IMiDs ® compound 65 non porcine pancreatic 65 PLK1 SNALP 65 ASONEP TM 65 FDA Accepts 65 AtuRNAi 65 Develop Novel 65 Posiphen TM 65 nilotinib Tasigna ® 65 OMP #R# 65 Sangamo BioSciences Announces 65 novel orally administered 65 Tyrima 65 Novosom 65 Granulocyte Colony Stimulating Factor 65 HuLuc# 65 small molecule glucokinase 65 pancreatic colon 65 HCV protease 65 Anti Infective 65 nucleoside tide 65 histone deacetylase HDAC inhibitor 65 Phase IIb Trial 65 gastro intestinal inflammation 65 Anti Tumor Activity 65 lead Aganocide compound 65 Aurora kinase 65 Signal Transduction 65 alvespimycin 65 HyACT 65 MGd 65 Genotyping Test 65 Awarded Qualifying Therapeutic 65 Humanized Anti 65 Hormone Refractory Prostate Cancer 65 Initiate Phase III 65 cyclin dependent kinase inhibitor 65 Demonstrates Sustained 65 MTP inhibitor 65 G Protein Coupled 65 Carfilzomib 65 chimeric monoclonal antibody 65 abnormal p# 65 Temsirolimus 65 poly ADP ribose polymerase 65 SPL# Gel vaginal microbicide 65 Randomized Phase 65 Nereus Pharmaceuticals 65 Exelixis XL# 65 subsidiaries visit http:/www.apricusbio.com 65 Dose Ranging Study 65 evaluating tivozanib 65 include VALSTAR TM 65 CYP#A# CYP#D# 65 Mouse Models 65 R sorafenib tablets 65 HGS ETR1 65 Protexia ® 65 Tramiprosate ALZHEMED TM 65 TNFerade TM 65 Symadex 65 Shows Statistically Significant 65 IMA# 65 Maribavir 65 deforolimus 65 Metabolic Disease 65 potently inhibits 65 hypoxia selective 65 Trophos 65 please visit www.advaxis.com 65 siRNA Delivery 65 5 HT2C serotonin 65 GRN# 65 See CLINICAL PHARMACOLOGY 65 mTOR kinase 65 Advanced Melanoma 65 Cloretazine 65 myelofibrosis polycythemia vera 65 Novel Antibiotic 65 HCV Protease Inhibitor 65 HuMax TAC 65 forodesine 65 Monoclonal Antibodies 65 folate analogue metabolic 64 small molecule tyrosine 64 metaglidasen 64 small molecule Hedgehog 64 drug conjugate 64 Receives Fast Track 64 AKIP ™ 64 dependent kinase inhibitor 64 Lung Cancer Drug 64 Pivotal Trial 64 Gentamicin Surgical Implant 64 Oracea TM 64 Syncria R 64 Demonstrates Efficacy 64 biologic therapeutics 64 dextromethorphan quinidine 64 Pediatric Oncology Branch 64 Virulizin ® 64 DGAT 64 c Raf kinase 64 proteasome inhibitor 64 Pharmos proprietary 64 Initiate Phase II 64 NeoLipid R 64 Pimavanserin 64 ZEVALIN ® 64 GMX# 64 molecular imaging radiopharmaceutical 64 EGFR HER2 64 Oral Fingolimod 64 Preclinical Development 64 p# inhibitor 64 Monoclonal antibody 64 Nicotine Vaccine 64 Confirms Efficacy 64 Tarvacin TM 64 taxane derivative 64 S#P# 64 Quark Biotech Inc. 64 personalized cellular immunotherapy 64 ALN HTT 64 Pivotal Study 64 ZYBRESTAT TM 64 Anticancer Compound 64 Receives Approvable Letter 64 GATTEX TM 64 evaluating mipomersen 64 Epeius Biotechnologies Corporation 64 Asthma COPD 64 tumor vascular disrupting 64 Genasense oblimersen sodium Injection 64 Announce License Agreement 64 Friedreich Ataxia FRDA 64 ProLindac TM 64 Sphingomab TM 64 Antibody Discovery 64 HyperAcute 64 JAK inhibitors 64 Luveniq 64 CCX# B 64 Investigational Compound 64 Agonist MABA program 64 AMPA kainate 64 CysDisplay R 64 Provectus Pharmaceuticals specializes 64 novel peptide 64 TRIOLEX ™ 64 RNAi therapeutic targeting 64 developing Zerenex ferric 64 Intravenous CP 64 Peginterferon alfa 2b 64 Wafer polifeprosan 64 Inc. AMEX YMI 64 Quinamed 64 Therapeutic Antibody 64 AE# vaccine 64 PDE4 64 HER2 ErbB2 64 Smooth Muscle 64 RNA antagonist 64 albiglutide currently 64 OMNARIS HFA 64 Receptor Agonist 64 romazarit 64 HSP# inhibitor 64 Cardioxyl Pharmaceuticals 64 PSMA ADC 64 erlotinib Tarceva ® 64 PRTX 64 platinum chemotherapeutic 64 Oral Insulin 64 Biomarker Study 64 5 HT6 64 epothilone 64 docetaxel Taxotere R 64 Aganocide R 64 ABL inhibitor 64 Tesmilifene 64 Nicotinic 64 Patient Enrolment 64 First Patient Enrolled 64 paclitaxel poliglumex 64 Investigational Treatment 64 www.pranabio.com 64 thetreatment 64 potently inhibit 64 Alocrest 64 Quark Biotech 64 Zorbtive TM 64 NS5A 64 refractory chronic lymphocytic 64 II Clinical Trial 64 A3 adenosine receptor 64 Hsp# inhibition 64 R lenalidomide 64 Dapagliflozin 64 Severe Sepsis 64 vascular disrupting agent 64 antisense inhibitor 64 VitiGam 64 JAK#/JAK# 64 Spectrum Pharmaceuticals Announces 64 Dose Ranging 64 Simulect 64 aurora kinase inhibitor 64 dopamine D2 64 Vidaza ® 64 bavituximab monotherapy trial 64 Neulasta R 64 adrenergic regulation 64 potent antiproliferative 64 Blinatumomab 64 product candidate Lpathomab 64 seliciclib CYC# 64 ACAPODENE R 64 M2 subunit 64 Isavuconazole 64 Therapeutic Efficacy 64 depsipeptide 64 PGL# 64 Single Dose 64 antiproliferative activity 64 anticancer therapeutics 64 initiated Phase 1b 64 Alnylam #x# 64 agonist compounds 64 Talactoferrin 64 SCIB1 64 Parathyroid Hormone 64 IMiD 64 CRMD# 64 Angiolix 64 Fc fusion protein 64 Fludara ® 64 Earns Milestone Payment 64 Polymorphisms 64 antibody blinatumomab MT#/MEDI-# 64 LEVADEX TM 64 volociximab 64 Denufosol 64 Triapine 64 humanised antibody 64 Pooled Analysis 64 Thiovir 64 TRANSDUR ® 64 evaluating satraplatin 64 Quark Pharmaceuticals 64 XYOTAX TM 64 Tumour VDA 64 HIV integrase inhibitor 64 novel orally bioavailable 64 PEGylated Fab fragment 64 JAK inhibitor 64 Locked Nucleic Acid LNA 64 Randomized Phase II 64 oral Janus kinase 64 Kahalalide F 64 HDAC inhibitor 64 var arrContent = 64 apoptosis proteins 64 Tarvacin Anti Cancer 64 Sphingomab 64 var arrMeta = 64 triciribine phosphate monohydrate 64 Cethromycin 64 Angiotensin Converting Enzyme 64 Patent Covering 64 Therapeutic Competitors companiesandmarkets.com adEgemonye 64 developing biomedical countermeasures 64 oral nucleoside analogue 64 Pharma Merck Serono 64 Late Breaker 64 diarrhea predominant irritable 64 vidofludimus 64 lucinactant 64 FOLFOX6 chemotherapy regimen 64 label Lipofen R 64 Insegia 64 HCV polymerase 64 alpha#beta# integrin 64 TÎ ² 4 64 Multiple Ascending Dose 64 TRACON Pharmaceuticals 64 selective angiogenic kinase inhibitor 64 geldanamycin 64 MORAb 64 SIX RO ROG 64 Issued Patent 64 Cyclooxygenase Inhibiting Nitric Oxide 64 ospemifene 64 mGluR2 positive 64 Orally Active 64 Activity Assay 64 iobenguane 64 Tumor Necrosis Factor 64 Delipidation 64 estrogen receptor antagonist 64 Tumor Angiogenesis 64 purinergic receptors P#X# 64 CRLX# 64 non nucleoside 64 Drug Shows Promise 64 Oncolytic 64 cervical breast 64 receptor partial agonist 64 selectively inhibited 64 Bortezomib 64 DNA RNA Medicines 63 CCR9 63 peptibody 63 Potelligent TM 63 INCB# [001] 63 FGFR 63 Oligonucleotide 63 Panzem NCD 63 Telatinib 63 Anticancer Agent 63 glucokinase activator 63 Monoclonal 63 TRX1 63 induced macular edema 63 adhesion molecule EpCAM expressing 63 Hematide ™ 63 rhMBL 63 IND Filing 63 Therapeutic Competitors Report 63 Peroxisome Proliferator Activated Receptor 63 oral isotype selective HDAC 63 beta 1a 63 Zenvia ™ 63 Cx# [002] 63 Uvidem 63 BiTE R 63 RGB # 63 dihydrochloride Tablets 63 HCV NS5B polymerase 63 polymerase inhibitor 63 peptide conjugated 63 CDK cyclin dependent 63 HepDirect prodrug 63 Antiviral Activity 63 Pruvel TM 63 tramiprosate Alzhemed TM 63 PNT# 63 Elotuzumab 63 Inotek Pharmaceuticals Corporation 63 Cotara ® 63 vaccine GMK 63 formerly LymphoStat B 63 HCV protease inhibitor 63 hypoxia inducible factor 63 HuMax 63 CD4 monoclonal antibody 63 selective inhibition 63 Transdermal Delivery 63 PORxin TM 63 Intarcia 63 Civacir 63 Pivotal Phase II 63 BRAF mutant 63 Prestara TM 63 VentiRx Pharmaceuticals 63 Phase 2a clinical trials 63 Gastric Cancer 63 adecatumumab MT# 63 Surfaxin LS 63 UPLYSO 63 Qutenza TM 63 dimebon latrepirdine 63 Synthetic Peptide 63 miRagen 63 Metaphore 63 Investigational Oral 63 BrachySil TM 63 samarium Sm 63 lintuzumab SGN 63 anti aging glycopeptides 63 MET VEGFR2 63 selective antagonist 63 Receive Milestone Payment 63 Anthrax Toxin 63 DiLA2 63 Vicriviroc 63 pharmacokinetic PK study 63 Pralatrexate 63 Cell Proliferation 63 Litx 63 certain protein tyrosine 63 immatics 63 R MSCRAMM 63 Study Evaluating 63 Cannabinor 63 castrate resistant prostate cancer 63 papillary renal cell carcinoma 63 Gamma secretase 63 Chemophase 63 HCV polymerase inhibitors 63 Captisol ® 63 CTAP# Capsules 63 carbohydrate polymer 63 Potent Inhibitor 63 Collaborators Publish 63 BioNumerik 63 Adenosine Therapeutics 63 Atopic Dermatitis 63 HuCNS SC ® 63 Boehringer Ingelheim MedImmune 63 EHT AGN 63 Innate Immune 63 CCR2 63 serious systemic Staphylococcal 63 Teva Provides Update 63 IRX 2 63 using ImmunoGen TAP 63 humanised monoclonal antibody 63 Signaling Pathway 63 Pertuzumab 63 Aganocide TM 63 Diasome 63 TRANSDUR ™ 63 Immunomedics Announces 63 Confirmatory Phase 63 Phase 2b Study 63 selective estrogen receptor modulator 63 antiproliferative effects 63 OTCBB IMUC 63 Zemiva TM 63 Cerebril TM 63 Entry Inhibitor 63 visit www.genenews.com 63 P#Y# [001] 63 Vitamin D analogue 63 Allovectin 7 R 63 Technosphere ® 63 pathophysiological effects 63 Quinamed R 63 immune stimulatory 63 PANVAC VF 63 nicotinic alpha 7 63 sapacitabine CYC# 63 NABTT 63 Neuroprotection 63 DOS# 63 humanized therapeutic 63 TransVax ™ 63 RNA antagonists 63 selectively inhibit replication 63 RNA Interference 63 delta opioid receptor 63 cardio metabolic diseases 63 epothilones 63 oral JAK1 63 RECOTHROM R 63 cortisol synthesis 63 R Saizen R 63 delta isoform 63 Panzem 63 biliary tract cancer 63 BiTE Antibody 63 Mucosal 63 Pegloticase 63 Transdermal Patch 63 HIV AIDS neuropathic pain 63 Veronate R 63 oral Hsp# inhibitor 63 submitted supplemental Biologics 63 GSK '# 63 DMD DMSc 63 SGLT Inhibitors 63 AT1R 63 candidate REP# 63 Biopharmaceuticals AG 63 PharmaNova 63 TRIOLEX HE# 63 LEP ETU 63 Mg Usa 63 SUTENT ® 63 synthetic retinoid 63 novel nucleoside analog 63 Kinases 63 Modulates 63 GVAX R 63 investigational immunotherapy 63 Guanilib 63 glucagon receptor 63 Presents Positive Preclinical 63 virus HCV protease inhibitor 63 Cutaneous T 63 novel antiviral therapeutics 63 compound PMX # 63 peripherally acting 63 Horizant ™ 63 Vitro Activity 63 Enzastaurin 63 DNA Methylation 63 proprietary PEGylation 63 Hormone Receptor 63 COLAZAL R 63 pharmacological chaperone 63 Chemokine 63 Empatic ™ 63 IMPACS R 63 selectively inhibits 63 targeting miR 63 delivers fluocinolone acetonide FA 63 XP# XP# 63 IND Application 63 cetuximab Erbitux R 63 anti botulism antibody 63 products MKC# PP 63 var arrUrl = 63 class mGluR5 inhibitor 63 proprietary capillary aerosolization 63 Tarceva TM 63 Etubics 63 ELND-#/AZD-# 63 PI3K inhibitor 63 R bortezomib 63 Anavex #-# 63 LHRH antagonists 63 Angiocept 63 Upregulation 63 ArQule Kinase Inhibitor 63 IgG1 antibody 63 entinostat 63 HIV integrase inhibitors 63 successfully commercialize Iluvien 63 selective inverse agonist 63 Proellex TM 63 vesicular monoamine transporter 63 Safinamide 63 Proxinium TM 63 neuronal nicotinic receptors NNRs 63 Tissue Repair 63 modulator SERM 63 Neutrolin ® 63 molecule epidermal 63 Eniluracil 63 Announce Collaboration Agreement